Lin Erin M, Sparano Anthony, Spalding Aaron, Eisbruch Avraham, Worden Francis P, Heth Jason, Sullivan Stephen E, Thompson B Gregory, Marentette Lawrence J
Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan.
Skull Base. 2010 Mar;20(2):61-7. doi: 10.1055/s-0029-1236165.
We present our experience with sinonasal undifferentiated carcinoma at the University of Michigan over 13 years and review prior published data. We conducted a retrospective review of 19 patients who presented to a tertiary care academic center multidisciplinary skull base clinic with sinonasal undifferentiated carcinoma between 1995 and 2008. Overall survival was 22% at 5 years, and the estimated 5-year distant metastasis-free survival was 35%. At 2 years, local control was 83%, regional control was 50%, and distant control was 83%. Local control was best in those patients treated nonsurgically, as was median survival, though this was not statistically significant. Nodal disease in the neck, either at presentation or at recurrence, was noted in 26% of patients. Survival for sinonasal undifferentiated carcinoma remains poor. It is possible that up-front radiation or chemoradiation will lead to better local control rates, though surgery remains a mainstay of treatment. In all cases, the cervical nodes should be addressed with primary treatment.
我们介绍了密歇根大学13年来在鼻窦未分化癌方面的经验，并回顾了之前发表的数据。我们对1995年至2008年间在一家三级医疗学术中心多学科颅底诊所就诊的鼻窦未分化癌患者进行了回顾性研究。5年总生存率为22%，预计5年无远处转移生存率为35%。2年时，局部控制率为83%，区域控制率为50%，远处控制率为83%。非手术治疗的患者局部控制最佳，中位生存期也是如此，不过这在统计学上无显著差异。26%的患者在初诊或复发时出现颈部淋巴结疾病。鼻窦未分化癌的生存率仍然很低。尽管手术仍是主要治疗手段，但 upfront 放疗或放化疗可能会带来更好的局部控制率。在所有病例中，颈部淋巴结应在初次治疗时予以处理。
